
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is well-positioned for future success due to its strong first quarter performance and positive outlook for future revenue growth. With a successful U.S. commercial launch and increasing sales forces, the company is expected to drive significant revenue growth in the coming years. Additionally, the pending results of the ACCCESS study could provide further opportunities for expansion in 2027. Overall, Nyxoah has the potential to become a high-growth asset in the medical technology market.
Bears say
Nyxoah is facing risks in terms of standard adoption and obtaining additional capital, especially in a market dominated by larger competitors. While 2026 may present some potential for investor confidence with the company's progress in commercialization and personnel updates, the lowered valuation multiple and potential regulatory risks associated with its ACCCESS study are concerning for its long-term potential and profitability. The company's success in the fourth quarter of 2025 may provide a temporary boost, but repeat orders in the first quarter of 2026 will be a key indicator of sustained commercial success.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares